Detail of "1951-56-0"

Reference

Hycanthone and other antischistosomal drugs: lack of obligatory association between chemotherapeutic effects and mutagenic activity

Hycanthone and other antischistosomal drugs: lack of obligatory association between chemotherapeutic effects and mutagenic activity. Bueding, E.; Batzinger, R. P. (Sch. Hyg. Public Health, Johns Hopkins Univ. 3105-97-3 is the cas registry number. This chemical is also mentioned in this article., Baltimore, Md., USA). Cold Spring Harbor Conf. Cell Proliferation, 4(Origins Hum. Cancer, Book A), 445-63 (English) 1977. CODEN: CSHCAL. ISSN: 0097-5230. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacodynamics) Several antischistosomal compds. were examd. for their mutagenic and carcinogenic activities. Hycanthone [3105-97-3] was a potent mutagen and a carcinogen as well. The nitroheterocyclic antischistosomal agents niridazole [61-57-4] and furapromidium [1951-56-0] were mutagenic whereas the former also showed carcinogenic activity. Metrifonate [52-68-6] and oxamniquine [21738-42-1] showed antischistosomal activities, but were much less mutagenic than hycanthone. A chloroindazole analog [24167-40-6] of hycanthone was equipotent to hycanthone as a schistosomicide, but was much less mutagenic. CGP 4540 (4-isothiocyanato-4'-nitrodiphenylamine) [26328-53-0], a relatively new schistosomicide, had no mutagenic activity in vitro, but excreted mutagenic metabolites when given orally and increased mutation frequency in host-mediated assay. A decrease of the intestinal bacterial flora of the host by antibacterial treatment prior to the administration of this isothiocyanate drug, prevented the formation of mutagenic metabolites and mutation in the host-mediated assay. Thus, there appears to be no correlation between the antischistosomal activity and mutagenicity of these drugs. .

Mutation induction by the antischistosomal drug F30066 in various test systems

Mutation induction by the antischistosomal drug F30066 in various test systems. Ong, Tong-Man; Callen, D. F.; Huang, Shiu Lan; Batzinger, Robert P.; Bueding, Ernest (Natl. Inst. Environ. Health Sci., Research Triangle Park, N. C., USA). Mutat. Res., 48(1), 37-42 (English) 1977. CODEN: MUREAV. DOCUMENT TYPE: Journal CA Section: 3 (Biochemical Interactions) Section cross-reference(s): 1 The antischistosomal drug F30066 (furapromidium)(I) [1951-56-0] was mutagenic in bacteria (Salmonella typhimurium), fungi (Neurospora crassa), and mammalian cells (Chinese hamster), and it caused gene conversions in Saccharomyces cerevisiae. Thus, the chemotherapeutic use of I for the treatment of schistosomiasis represents a potential mutagenic and possibly carcinogenic hazard to man. Although I did not appear to be a particularly potent mutagen, the mutagenic activity obsd. in these systems resulted from exposure times and concns. that were quite low compared with those involved in the treatment of schistosomiasis.